Patent Board Denies Roxane Request For Inter Partes Review
ALEXANDRIA, Va. — A Novartis AG patent covering a tumor treatment will not be the subject of an upcoming inter partes review (IPR), the Patent Trial and Appeal Board announced Feb....To view the full article, register now.
Already a subscriber? Click here to view full article